Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-label Study of the Effects of Percutaneous Administration of an Extracellular Matrix Hydrogel, VentriGel, Following Myocardial Infarction

NCT02305602 is registered in ClinicalTrials.gov with Ventrix, Inc. as lead sponsor.

NCT NCT02305602
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02305602 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-label Study of the Effects of Percutaneous Administration of an Extracellular Matrix Hydrogel, VentriGel, Following Myocardial Infarction
Lead sponsor
Ventrix, Inc.
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2015
Completion date
June 30, 2019
Enrollment
15 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure, left ventricular remodeling, myocardial infarction